schliessen

Filtern

 

Bibliotheken

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have impr... Full description

Journal Title: The Lancet (British edition) 2015, Vol.385 (9987), p.2606-2615
Main Author: Sax, Paul E, Dr Prof
Other Authors: Wohl, David, MD , Yin, Michael T, Prof , Post, Frank, MD , DeJesus, Edwin, MD , Saag, Michael, MD , Pozniak, Anton, MD , Thompson, Melanie, MD , Podzamczer, Daniel, MD , Molina, Jean Michel, Prof , Oka, Shinichi, MD , Koenig, Ellen, MD , Trottier, Benoit, MD , Andrade-Villanueva, Jaime, MD , Crofoot, Gordon, MD , Custodio, Joseph M, PharmD , Plummer, Andrew, MS , Zhong, Lijie, PhD , Cao, Huyen, MD , Martin, Hal, MD , Callebaut, Christian, PhD , Cheng, Andrew K, MD , Fordyce, Marshall W, MD , McCallister, Scott, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
HIV
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/25890673
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_1691310963
title: Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
format: Article
creator:
  • Sax, Paul E, Dr Prof
  • Wohl, David, MD
  • Yin, Michael T, Prof
  • Post, Frank, MD
  • DeJesus, Edwin, MD
  • Saag, Michael, MD
  • Pozniak, Anton, MD
  • Thompson, Melanie, MD
  • Podzamczer, Daniel, MD
  • Molina, Jean Michel, Prof
  • Oka, Shinichi, MD
  • Koenig, Ellen, MD
  • Trottier, Benoit, MD
  • Andrade-Villanueva, Jaime, MD
  • Crofoot, Gordon, MD
  • Custodio, Joseph M, PharmD
  • Plummer, Andrew, MS
  • Zhong, Lijie, PhD
  • Cao, Huyen, MD
  • Martin, Hal, MD
  • Callebaut, Christian, PhD
  • Cheng, Andrew K, MD
  • Fordyce, Marshall W, MD
  • McCallister, Scott, MD
subjects:
  • Acquired immune deficiency syndrome
  • Adenine - administration & dosage
  • Adenine - adverse effects
  • Adenine - analogs & derivatives
  • Adult
  • AIDS
  • Analysis
  • Anti-HIV Agents - adverse effects
  • Anti-HIV Agents - therapeutic use
  • Antiretroviral drugs
  • Arthralgia - chemically induced
  • Bone Density - drug effects
  • Carbamates - administration & dosage
  • Carbamates - adverse effects
  • CD4 Lymphocyte Count
  • Clinical trials
  • Cobicistat
  • Cross infection
  • Deoxycytidine - administration & dosage
  • Deoxycytidine - adverse effects
  • Deoxycytidine - analogs & derivatives
  • Double-Blind Method
  • Drug Combinations
  • Drug therapy
  • Emtricitabine
  • Female
  • Headache - chemically induced
  • Health aspects
  • HIV
  • HIV (Viruses)
  • HIV infection
  • HIV Infections - drug therapy
  • HIV Infections - virology
  • Human immunodeficiency virus
  • Humans
  • immune system diseases
  • Infections
  • Internal Medicine
  • Kidney - drug effects
  • Male
  • Medical colleges
  • Nausea
  • Nosocomial infections
  • Organophosphonates - administration & dosage
  • Organophosphonates - adverse effects
  • Quinolones - administration & dosage
  • Quinolones - adverse effects
  • Respiration Disorders - chemically induced
  • Sleep Initiation and Maintenance Disorders - chemically induced
  • Tenofovir
  • Thiazoles - administration & dosage
  • Thiazoles - adverse effects
  • Treatment Outcome
  • Viral Load - drug effects
  • virus diseases
ispartof: The Lancet (British edition), 2015, Vol.385 (9987), p.2606-2615
description: Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. Methods In these two controlled, double-blind phase 3 studies, we recruited treatment-naive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178 outpatient centres in 16 countries. Patients were randomly assigned (1:1) to receive once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo. Randomisation was done by a computer-generated allocation sequence (block size 4) and was stratified by HIV-1 RNA, CD4 count, and region (USA or ex-USA). Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary intention-to-treat efficacy and safety analyses. The main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the the US Food and Drug Adminstration (FDA) snapshot algorithm (pre-specified non-inferiority margin of 12%) and pre-specified renal and bone endpoints at 48 weeks. These studies are registered with ClinicalTrials.gov , numbers NCT01780506 and NCT01797445. Findings We recruited patients from Jan 22, 2013, to Nov 4, 2013 (2175 screened and 1744 randomly assigned), and gave treatment to 1733 patients (866 given E/C/F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate). E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in the tenofovir alafenamide group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copies per mL (adjusted difference 2·0%, 95% CI −0·7 to 4·7). Patients given E/C/F/tenofovir alafenamide had significantly smaller mean serum creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0·08 vs 0·12 mg/dL; p
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.837567
LOCALfalse
PrimoNMBib
record
control
sourceidgale_opena
recordidTN_cdi_proquest_journals_1691310963
sourceformatXML
sourcesystemPC
galeidA518061159
sourcerecordidA518061159
originalsourceidFETCH-LOGICAL-1878t-14260c6aca81ff3e353da3ff288b02f6e01ce962dccaf85bc207b3d8087ce2b83
addsrcrecordideNqNk99qFDEUxgdRbK0-ghLwRmGnJvNvZxSUUtQWCl5YZe9CJjnZps4ka5LZ2tf1STyzq9ttKbYMJCTn-35JzpyTJM8Z3WeUVW--UlbQtJrm1StWvq5oxap09iDZZcW0SMtiOnuY7G4kO8mTEM4ppUVFy8fJTlbWDcXAbvL7FKzTbmk8EZ3QYEVvFJAl-DAEEjdBZYJbePfLdEQPvfAiwoRIDPp-6HChyIWJZwS6pYkw9wI9Y7w10oQo4oQIqwj00eNGFK2xaEczMdZEIzoSPYjYg43EaXJ0_D1lGNIgo3H2LYkXjngkuN4EUBOi3NB2kLadsbhanIkAJJ8Q62w6urxx3sRLhCI6PE0eaZzg2d95L_n26ePp4VF68uXz8eHBScrqaR1TVmQVlZWQomZa55CXuRK51lldtzTTFVAmoakyJaXQddnKjE7bXNW0nkrI2jrfS47XXLfANBoPfOENpuqSO2G4shC5U7ygTcGBqpZJlkHeNLJiWgmQVZ432ZRmBVCKrJdrFub85wAh8nM3eIvX56xqWM5og_qNai464PhyF72QmCPJD0pWY02wsvmvqshYzQoEomr_FhV-CnojnQVtcP8a9l6G7RNe3GLg28TJlqAdAlZJwCGY-VkMczGEcP0C95BvH1-u5dK7EDzoze9hlI8txVctxcd-4azkq5bis6trL4a2B7Vx_eshFLy7AR5LfCxcfJ_p7sR_WLsBS3NpwPMgDVgJCitIRq6cuZPw_gZBYl8YKbofcAnhqnB4yDhdQ0YGK1eEWf4HnklX5w
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1691310963
display
typearticle
titleTenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
sourceAlma/SFX Local Collection
creatorSax, Paul E, Dr Prof ; Wohl, David, MD ; Yin, Michael T, Prof ; Post, Frank, MD ; DeJesus, Edwin, MD ; Saag, Michael, MD ; Pozniak, Anton, MD ; Thompson, Melanie, MD ; Podzamczer, Daniel, MD ; Molina, Jean Michel, Prof ; Oka, Shinichi, MD ; Koenig, Ellen, MD ; Trottier, Benoit, MD ; Andrade-Villanueva, Jaime, MD ; Crofoot, Gordon, MD ; Custodio, Joseph M, PharmD ; Plummer, Andrew, MS ; Zhong, Lijie, PhD ; Cao, Huyen, MD ; Martin, Hal, MD ; Callebaut, Christian, PhD ; Cheng, Andrew K, MD ; Fordyce, Marshall W, MD ; McCallister, Scott, MD
creatorcontribSax, Paul E, Dr Prof ; Wohl, David, MD ; Yin, Michael T, Prof ; Post, Frank, MD ; DeJesus, Edwin, MD ; Saag, Michael, MD ; Pozniak, Anton, MD ; Thompson, Melanie, MD ; Podzamczer, Daniel, MD ; Molina, Jean Michel, Prof ; Oka, Shinichi, MD ; Koenig, Ellen, MD ; Trottier, Benoit, MD ; Andrade-Villanueva, Jaime, MD ; Crofoot, Gordon, MD ; Custodio, Joseph M, PharmD ; Plummer, Andrew, MS ; Zhong, Lijie, PhD ; Cao, Huyen, MD ; Martin, Hal, MD ; Callebaut, Christian, PhD ; Cheng, Andrew K, MD ; Fordyce, Marshall W, MD ; McCallister, Scott, MD ; GS-US-292-0104/0111 Study Team
descriptionSummary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. Methods In these two controlled, double-blind phase 3 studies, we recruited treatment-naive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178 outpatient centres in 16 countries. Patients were randomly assigned (1:1) to receive once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo. Randomisation was done by a computer-generated allocation sequence (block size 4) and was stratified by HIV-1 RNA, CD4 count, and region (USA or ex-USA). Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary intention-to-treat efficacy and safety analyses. The main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the the US Food and Drug Adminstration (FDA) snapshot algorithm (pre-specified non-inferiority margin of 12%) and pre-specified renal and bone endpoints at 48 weeks. These studies are registered with ClinicalTrials.gov , numbers NCT01780506 and NCT01797445. Findings We recruited patients from Jan 22, 2013, to Nov 4, 2013 (2175 screened and 1744 randomly assigned), and gave treatment to 1733 patients (866 given E/C/F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate). E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in the tenofovir alafenamide group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copies per mL (adjusted difference 2·0%, 95% CI −0·7 to 4·7). Patients given E/C/F/tenofovir alafenamide had significantly smaller mean serum creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0·08 vs 0·12 mg/dL; p<0·0001), significantly less proteinuria (median % change −3 vs 20; p<0·0001), and a significantly smaller decrease in bone mineral density at spine (mean % change −1·30 vs –2·86; p<0·0001) and hip (−0·66 vs –2·95; p<0·0001) at 48 weeks. Interpretation Through 48 weeks, more than 90% of patients given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success. Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide. Although these studies do not have the power to assess clinical safety events such as renal failure and fractures, our data suggest that E/C/F/tenofovir alafenamide will have a favourable long-term renal and bone safety profile. Funding Gilead Sciences.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(15)60616-X
3PMID: 25890673
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subject
ispartofThe Lancet (British edition), 2015, Vol.385 (9987), p.2606-2615
rights
0Elsevier Ltd
12015 Elsevier Ltd
2Copyright © 2015 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2015 Elsevier B.V.
4Copyright Elsevier Limited Jun 27, 2015
lds50peer_reviewed
citedbyFETCH-LOGICAL-1878t-14260c6aca81ff3e353da3ff288b02f6e01ce962dccaf85bc207b3d8087ce2b83
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25890673$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Sax, Paul E, Dr Prof
1Wohl, David, MD
2Yin, Michael T, Prof
3Post, Frank, MD
4DeJesus, Edwin, MD
5Saag, Michael, MD
6Pozniak, Anton, MD
7Thompson, Melanie, MD
8Podzamczer, Daniel, MD
9Molina, Jean Michel, Prof
10Oka, Shinichi, MD
11Koenig, Ellen, MD
12Trottier, Benoit, MD
13Andrade-Villanueva, Jaime, MD
14Crofoot, Gordon, MD
15Custodio, Joseph M, PharmD
16Plummer, Andrew, MS
17Zhong, Lijie, PhD
18Cao, Huyen, MD
19Martin, Hal, MD
20Callebaut, Christian, PhD
21Cheng, Andrew K, MD
22Fordyce, Marshall W, MD
23McCallister, Scott, MD
24GS-US-292-0104/0111 Study Team
title
0Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. Methods In these two controlled, double-blind phase 3 studies, we recruited treatment-naive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178 outpatient centres in 16 countries. Patients were randomly assigned (1:1) to receive once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo. Randomisation was done by a computer-generated allocation sequence (block size 4) and was stratified by HIV-1 RNA, CD4 count, and region (USA or ex-USA). Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary intention-to-treat efficacy and safety analyses. The main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the the US Food and Drug Adminstration (FDA) snapshot algorithm (pre-specified non-inferiority margin of 12%) and pre-specified renal and bone endpoints at 48 weeks. These studies are registered with ClinicalTrials.gov , numbers NCT01780506 and NCT01797445. Findings We recruited patients from Jan 22, 2013, to Nov 4, 2013 (2175 screened and 1744 randomly assigned), and gave treatment to 1733 patients (866 given E/C/F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate). E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in the tenofovir alafenamide group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copies per mL (adjusted difference 2·0%, 95% CI −0·7 to 4·7). Patients given E/C/F/tenofovir alafenamide had significantly smaller mean serum creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0·08 vs 0·12 mg/dL; p<0·0001), significantly less proteinuria (median % change −3 vs 20; p<0·0001), and a significantly smaller decrease in bone mineral density at spine (mean % change −1·30 vs –2·86; p<0·0001) and hip (−0·66 vs –2·95; p<0·0001) at 48 weeks. Interpretation Through 48 weeks, more than 90% of patients given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success. Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide. Although these studies do not have the power to assess clinical safety events such as renal failure and fractures, our data suggest that E/C/F/tenofovir alafenamide will have a favourable long-term renal and bone safety profile. Funding Gilead Sciences.
subject
0Acquired immune deficiency syndrome
1Adenine - administration & dosage
2Adenine - adverse effects
3Adenine - analogs & derivatives
4Adult
5AIDS
6Analysis
7Anti-HIV Agents - adverse effects
8Anti-HIV Agents - therapeutic use
9Antiretroviral drugs
10Arthralgia - chemically induced
11Bone Density - drug effects
12Carbamates - administration & dosage
13Carbamates - adverse effects
14CD4 Lymphocyte Count
15Clinical trials
16Cobicistat
17Cross infection
18Deoxycytidine - administration & dosage
19Deoxycytidine - adverse effects
20Deoxycytidine - analogs & derivatives
21Double-Blind Method
22Drug Combinations
23Drug therapy
24Emtricitabine
25Female
26Headache - chemically induced
27Health aspects
28HIV
29HIV (Viruses)
30HIV infection
31HIV Infections - drug therapy
32HIV Infections - virology
33Human immunodeficiency virus
34Humans
35immune system diseases
36Infections
37Internal Medicine
38Kidney - drug effects
39Male
40Medical colleges
41Nausea
42Nosocomial infections
43Organophosphonates - administration & dosage
44Organophosphonates - adverse effects
45Quinolones - administration & dosage
46Quinolones - adverse effects
47Respiration Disorders - chemically induced
48Sleep Initiation and Maintenance Disorders - chemically induced
49Tenofovir
50Thiazoles - administration & dosage
51Thiazoles - adverse effects
52Treatment Outcome
53Viral Load - drug effects
54virus diseases
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqNk99qFDEUxgdRbK0-ghLwRmGnJvNvZxSUUtQWCl5YZe9CJjnZps4ka5LZ2tf1STyzq9ttKbYMJCTn-35JzpyTJM8Z3WeUVW--UlbQtJrm1StWvq5oxap09iDZZcW0SMtiOnuY7G4kO8mTEM4ppUVFy8fJTlbWDcXAbvL7FKzTbmk8EZ3QYEVvFJAl-DAEEjdBZYJbePfLdEQPvfAiwoRIDPp-6HChyIWJZwS6pYkw9wI9Y7w10oQo4oQIqwj00eNGFK2xaEczMdZEIzoSPYjYg43EaXJ0_D1lGNIgo3H2LYkXjngkuN4EUBOi3NB2kLadsbhanIkAJJ8Q62w6urxx3sRLhCI6PE0eaZzg2d95L_n26ePp4VF68uXz8eHBScrqaR1TVmQVlZWQomZa55CXuRK51lldtzTTFVAmoakyJaXQddnKjE7bXNW0nkrI2jrfS47XXLfANBoPfOENpuqSO2G4shC5U7ygTcGBqpZJlkHeNLJiWgmQVZ432ZRmBVCKrJdrFub85wAh8nM3eIvX56xqWM5og_qNai464PhyF72QmCPJD0pWY02wsvmvqshYzQoEomr_FhV-CnojnQVtcP8a9l6G7RNe3GLg28TJlqAdAlZJwCGY-VkMczGEcP0C95BvH1-u5dK7EDzoze9hlI8txVctxcd-4azkq5bis6trL4a2B7Vx_eshFLy7AR5LfCxcfJ_p7sR_WLsBS3NpwPMgDVgJCitIRq6cuZPw_gZBYl8YKbofcAnhqnB4yDhdQ0YGK1eEWf4HnklX5w
startdate2015
enddate2015
creator
0Sax, Paul E, Dr Prof
1Wohl, David, MD
2Yin, Michael T, Prof
3Post, Frank, MD
4DeJesus, Edwin, MD
5Saag, Michael, MD
6Pozniak, Anton, MD
7Thompson, Melanie, MD
8Podzamczer, Daniel, MD
9Molina, Jean Michel, Prof
10Oka, Shinichi, MD
11Koenig, Ellen, MD
12Trottier, Benoit, MD
13Andrade-Villanueva, Jaime, MD
14Crofoot, Gordon, MD
15Custodio, Joseph M, PharmD
16Plummer, Andrew, MS
17Zhong, Lijie, PhD
18Cao, Huyen, MD
19Martin, Hal, MD
20Callebaut, Christian, PhD
21Cheng, Andrew K, MD
22Fordyce, Marshall W, MD
23McCallister, Scott, MD
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BKMMT
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
76CLFQK
sort
creationdate2015
titleTenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
authorSax, Paul E, Dr Prof ; Wohl, David, MD ; Yin, Michael T, Prof ; Post, Frank, MD ; DeJesus, Edwin, MD ; Saag, Michael, MD ; Pozniak, Anton, MD ; Thompson, Melanie, MD ; Podzamczer, Daniel, MD ; Molina, Jean Michel, Prof ; Oka, Shinichi, MD ; Koenig, Ellen, MD ; Trottier, Benoit, MD ; Andrade-Villanueva, Jaime, MD ; Crofoot, Gordon, MD ; Custodio, Joseph M, PharmD ; Plummer, Andrew, MS ; Zhong, Lijie, PhD ; Cao, Huyen, MD ; Martin, Hal, MD ; Callebaut, Christian, PhD ; Cheng, Andrew K, MD ; Fordyce, Marshall W, MD ; McCallister, Scott, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1878t-14260c6aca81ff3e353da3ff288b02f6e01ce962dccaf85bc207b3d8087ce2b83
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Acquired immune deficiency syndrome
1Adenine - administration & dosage
2Adenine - adverse effects
3Adenine - analogs & derivatives
4Adult
5AIDS
6Analysis
7Anti-HIV Agents - adverse effects
8Anti-HIV Agents - therapeutic use
9Antiretroviral drugs
10Arthralgia - chemically induced
11Bone Density - drug effects
12Carbamates - administration & dosage
13Carbamates - adverse effects
14CD4 Lymphocyte Count
15Clinical trials
16Cobicistat
17Cross infection
18Deoxycytidine - administration & dosage
19Deoxycytidine - adverse effects
20Deoxycytidine - analogs & derivatives
21Double-Blind Method
22Drug Combinations
23Drug therapy
24Emtricitabine
25Female
26Headache - chemically induced
27Health aspects
28HIV
29HIV (Viruses)
30HIV infection
31HIV Infections - drug therapy
32HIV Infections - virology
33Human immunodeficiency virus
34Humans
35immune system diseases
36Infections
37Internal Medicine
38Kidney - drug effects
39Male
40Medical colleges
41Nausea
42Nosocomial infections
43Organophosphonates - administration & dosage
44Organophosphonates - adverse effects
45Quinolones - administration & dosage
46Quinolones - adverse effects
47Respiration Disorders - chemically induced
48Sleep Initiation and Maintenance Disorders - chemically induced
49Tenofovir
50Thiazoles - administration & dosage
51Thiazoles - adverse effects
52Treatment Outcome
53Viral Load - drug effects
54virus diseases
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Sax, Paul E, Dr Prof
1Wohl, David, MD
2Yin, Michael T, Prof
3Post, Frank, MD
4DeJesus, Edwin, MD
5Saag, Michael, MD
6Pozniak, Anton, MD
7Thompson, Melanie, MD
8Podzamczer, Daniel, MD
9Molina, Jean Michel, Prof
10Oka, Shinichi, MD
11Koenig, Ellen, MD
12Trottier, Benoit, MD
13Andrade-Villanueva, Jaime, MD
14Crofoot, Gordon, MD
15Custodio, Joseph M, PharmD
16Plummer, Andrew, MS
17Zhong, Lijie, PhD
18Cao, Huyen, MD
19Martin, Hal, MD
20Callebaut, Christian, PhD
21Cheng, Andrew K, MD
22Fordyce, Marshall W, MD
23McCallister, Scott, MD
24GS-US-292-0104/0111 Study Team
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Gale General OneFile (A&I only)
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75OpenAIRE
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Sax, Paul E, Dr Prof
1Wohl, David, MD
2Yin, Michael T, Prof
3Post, Frank, MD
4DeJesus, Edwin, MD
5Saag, Michael, MD
6Pozniak, Anton, MD
7Thompson, Melanie, MD
8Podzamczer, Daniel, MD
9Molina, Jean Michel, Prof
10Oka, Shinichi, MD
11Koenig, Ellen, MD
12Trottier, Benoit, MD
13Andrade-Villanueva, Jaime, MD
14Crofoot, Gordon, MD
15Custodio, Joseph M, PharmD
16Plummer, Andrew, MS
17Zhong, Lijie, PhD
18Cao, Huyen, MD
19Martin, Hal, MD
20Callebaut, Christian, PhD
21Cheng, Andrew K, MD
22Fordyce, Marshall W, MD
23McCallister, Scott, MD
aucorpGS-US-292-0104/0111 Study Team
formatjournal
genrearticle
ristypeJOUR
atitleTenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
jtitleThe Lancet (British edition)
addtitleLancet
date2015
risdate2015
volume385
issue9987
spage2606
epage2615
pages2606-2615
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. Methods In these two controlled, double-blind phase 3 studies, we recruited treatment-naive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178 outpatient centres in 16 countries. Patients were randomly assigned (1:1) to receive once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo. Randomisation was done by a computer-generated allocation sequence (block size 4) and was stratified by HIV-1 RNA, CD4 count, and region (USA or ex-USA). Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary intention-to-treat efficacy and safety analyses. The main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the the US Food and Drug Adminstration (FDA) snapshot algorithm (pre-specified non-inferiority margin of 12%) and pre-specified renal and bone endpoints at 48 weeks. These studies are registered with ClinicalTrials.gov , numbers NCT01780506 and NCT01797445. Findings We recruited patients from Jan 22, 2013, to Nov 4, 2013 (2175 screened and 1744 randomly assigned), and gave treatment to 1733 patients (866 given E/C/F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate). E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in the tenofovir alafenamide group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copies per mL (adjusted difference 2·0%, 95% CI −0·7 to 4·7). Patients given E/C/F/tenofovir alafenamide had significantly smaller mean serum creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0·08 vs 0·12 mg/dL; p<0·0001), significantly less proteinuria (median % change −3 vs 20; p<0·0001), and a significantly smaller decrease in bone mineral density at spine (mean % change −1·30 vs –2·86; p<0·0001) and hip (−0·66 vs –2·95; p<0·0001) at 48 weeks. Interpretation Through 48 weeks, more than 90% of patients given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success. Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide. Although these studies do not have the power to assess clinical safety events such as renal failure and fractures, our data suggest that E/C/F/tenofovir alafenamide will have a favourable long-term renal and bone safety profile. Funding Gilead Sciences.
copEngland
pubElsevier Ltd
pmid25890673
doi10.1016/S0140-6736(15)60616-X